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Autoantibodies against a panoply of self-antigens are seen in systemic lupus erythemato-
sus, but only a few (anti-Sm/RNP, anti-Ro/La, anti-dsDNA) are common. The common
lupus autoantigens are nucleic acid complexes and levels of autoantibodies can be
extraordinarily high. We explore why that is the case. Lupus is associated with impaired
central or peripheral B-cell tolerance and increased circulating autoreactive B cells.
However, terminal differentiation is necessary for autoantibody production. Nucleic acid
components of the major lupus autoantigens are immunostimulatory ligands for toll-like
receptor (TLR)7 or TLR9 that promote plasma cell differentiation. We show that the levels
of autoantibodies against the U1A protein (part of a ribonucleoprotein) are markedly higher
than autoantibodies against other antigens, including dsDNA and the non-nucleic acid-
associated autoantigens insulin and thyroglobulin. In addition to driving autoantibody
production, TLR7 engagement is likely to contribute to the pathogenesis of inflammatory
disease in lupus.
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The production of autoantibodies, in particular antinuclear antibodies (ANA), is nearly universal
among patients with systemic lupus erythematosus (SLE). Autoantibodies against a wide diversity
of cellular antigens (180 by one count) have been reported (1). However, the common autoantibody
“phenotypes” in this disease are not nearly as diverse as suggested by the list of known autoantibod-
ies. We argue that abnormal B-cell censoring accounts for the diversity of autoantibodies that can be
detected in SLE patients’ sera by sensitive techniques such as ELISA, whereas the highly restricted list
of commonly produced, high-level autoantibodies is a consequence of innate immune recognition
of autologous (immunostimulatory), nucleic acids associated with these antigens.
Multiple Mechanisms Limit Autoantibody Production
Positive and negative signals derived from the B-cell receptor (BCR) and co-receptors along with
competition for survival factors such as B-cell activating factor (BAFF, also known as BLyS),
determine whether a B-cell is activated, deleted, or rendered anergic (2, 3). Regulatory T cells play an
additional role in determining the outcome of positive and negative signals. Genetic abnormalities
affecting BCR signaling can lead to increased numbers of circulating autoreactive B cells.
The early B-cell repertoire in the bone marrow (BM) consists of many BCRs displaying
affinity for self-antigens, such as DNA. B cells expressing receptors with high affinity for self-
antigens expressed in the BM typically are deleted before they can exit the BM or else undergo
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receptor editing to generate a receptor without self-reactivity.
However, B cells that bind self-antigens weakly or recognize self-
antigens not found in the BM can exit to the periphery, where
they are censored by deletion or anergy-induction. A second
wave of autoreactive B cells is generated peripherally in germi-
nal centers (GC) as a consequence of somatic hypermutation
of the immunoglobulin heavy and light chain variable regions.
A single mutation in one of these regions can convert a BCR
with specificity for a bacterial antigen (phosphorylcholine) into
a receptor with specificity for DNA (4). About 40% of immature,
newly emigrated peripheral blood B cells from healthy individ-
uals are autoreactive as determined by HEp-2 cell lysate ELISA
(5). However, these cells are subject to censoring between the
immature and naïve B-cell stages of development and do not
secrete immunoglobulin unless they undergo further maturation
and terminal differentiation into plasma cells. Thus, in addition
to the censoring (central and peripheral) of autoreactive B cells,
regulation of terminal B-cell differentiation may limit production
of serum autoantibodies.
Abnormal Censoring of Autoreactive
B Cells in SLE
B cells from patients with SLE and mice with lupus-like disease
exhibit abnormalities that alter the strength of BCR signaling and
increase the generation of autoreactive B cells due to impaired cen-
tral and/or peripheral censoring. Examples include abnormalities
affecting PTPN22, Bruton’s tyrosine kinase (Btk), and Lyn, and
BAFF (Tnfsf13b).
PTPN22
Polymorphism of the protein tyrosine phosphatase PTPN22 is
associated with several autoimmune disorders characterized by
autoantibody production, including SLE, Type 1 diabetes (T1D),
rheumatoid arthritis, Grave’s disease, and myasthenia gravis
(6). The C1858T polymorphism decreases B-cell responsiveness,
impairing central deletion and editing of autoreactive B cells,
leading to autoantibody production (6, 7).
Bruton’s Tyrosine Kinase
Transgenic expression of Btk in mice impairs both central and
peripheral B-cell tolerance by altering the threshold for B-cell acti-
vation and reducing negative selection of autoreactive B cells (8).
BCR hyper-responsiveness in these mice promotes spontaneous
GC formation, a common finding in lupus-like autoimmune syn-
dromes, as well as the production of ANAs and development of
renal, lung, and salivary gland pathology.
Lyn
Mice with B-cell-specific deficiency of the tyrosine kinase Lyn
develop anti-dsDNA and anti-Sm autoantibodies and nephritis.
SLE patients with low LYN expression also have been reported
(9). Due to enhanced signaling in transitional and follicular B cells
and increased levels of BAFF, Lyn-deficient mice have abnormal
peripheral censoring and develop increased numbers of B1a cells
with abnormal GC formation (10). Autoimmunity is abolished by
deficiency of the adapter protein MyD88, suggesting that toll-like
receptors (TLRs) are involved.
B-Cell Activating Factor
Expression of transgenic Tnfsf13b (encoding BAFF) in mice alters
peripheral B-cell tolerance. Follicular and marginal zone B cells
compete for a limiting amount of this B-cell survival factor,
and increased BAFF levels allow autoreactive B cells to escape
censoring, resulting in increased GC formation, autoantibody
production, and the development of glomerulonephritis (11, 12).
Increased BAFF levels also are seen in SLE patients (13). Autoan-
tibody production in BAFF-transgenicmice is T-cell-independent
and MyD88/TLR-dependent (14).
Regulation of Terminal B-Cell
Differentiation
B-cell signaling defects affecting central or peripheral tolerance
increase the number of circulating autoreactive B cells, but not
necessarily their maturation into autoantibody-secreting plasma
cells. The restriction of terminal B-cell differentiation may limit
autoantibody production once autoreactive B cells have escaped
censoring. Plasma cell differentiation is controlled by two sets
of mutually antagonistic transcription factors. The B-cell gene
expression program is maintained by PAX5 and BCL-6, whereas
BLIMP-1 (PRDM1 gene) and XBP1 promote the generation and
survival of plasma cells (15). PAX5 and BCL-6 repress PRDM1
and PAX5 also represses XBP1. Conversely, BLIMP-1 represses
BCL-6 and PAX5. In GCs, B-cell activation via the BCR, T cells
(CD40–CD40L interactions), and/or TLR signaling causes NF-
κB-mediated up-regulation of IRF4, which induces PRDM1while
repressing BCL-6. IRF4 also is up-regulated by BAFF-stimulated
NF-κB activation, a potentially important pathway in BAFF-
transgenic mice (14).
The transcription factor STAT3 also up-regulates PRDM1
expression and is activated by the cytokines IL-10, IL-21, IL-6,
and IFNα (15). T-cell-dependent terminal differentiation of IgGB
cells is abolished in STAT3-deficient mice (16). BAFF acts syner-
gistically with MyD88 (TLR) (14) and with IL-21 (17), and TLR7
acts synergistically with T-cell-derived signals (CD40–CD40L and
SAP) to drive plasma cell differentiation (18).
Long- vs. Short-Lived Plasma Cells
Regulation of autoantibody levels also depends on the lifespan of
autoantibody-producing plasma cells. Plasma cells can be gener-
ated either as a product of GC reactions or extrafollicularly. Both
pathways regulate human autoantibody production. GC-derived
plasma cells have a propensity to home to the BM where they
survive and can secrete immunoglobulin for many years as long-
lived plasma cells, whereas plasma cells generated outside of GCs
(extrafollicular) usually are short-lived, secreting immunoglobu-
lin for a week or two before undergoing apoptosis. The persis-
tence of high levels of anti-Sm/RNP and Ro/La autoantibodies
in SLE is most consistent with a GC-derived long-lived plasma
cells and memory B cells. In contrast, the transitory presence
of anti-dsDNA autoantibodies during disease flares is most con-
sistent with production of these autoantibodies by short-lived
plasma cells. Further, the inconsistent response of anti-dsDNA
autoantibody levels to rituximab (anti-CD20 monoclonal anti-
body) therapy supports the existence of autoantibody-producing
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short- and long-lived plasma cells (19, 20). In our experience,
levels of autoantibodies against RNA-associated autoantigens such
as anti-Ro (SS-A) generally have been less responsive to rituximab
than anti-dsDNA autoantibodies. Since plasma cells are CD20-
negative, the degree to which autoantibody levels decline follow-
ing rituximab infusion may be an indicator of the relative con-
tribution of short-lived plasma cells to maintaining autoantibody
levels.
Follicular vs. Extrafollicular Pathways
Germinal center responses are characterized by a requirement
for T follicular helper (TFH) cells, production of class-switched
and somatically mutated antibodies, and generation of long-lived
plasma cells and memory B cells. T-cell expression of BCL-6
is critical for both GC and extrafollicular B-cell responses (21).
TFH cells (GC pathway) generally are Bcl-6+, PD-1hi, whereas T
cells involved in extrafollicular B-cell responses are Bcl-6+, PD-
1lo/int. An expanded population of circulating PD-1hi TFH-like
cells is seen in patients with active SLE and is associated with the
number of circulating plasmablasts and anti-dsDNAautoantibody
positivity; these cells may be a surrogate for aberrant GC activity
in SLE (22).
Mice homozygous for a mutation of the ubiquitin ligase Roquin
(sanroque mice) also accumulate TFH cells (23). IL-21 production
by TFH enhances class switching and plasma cell differentiation
by increasing the expression of activation-induced cytidine deam-
inase and BLIMP-1, promoting autoantibody production (24).
As GC B cells compete for limited numbers of TFH cells, the
increased CD40–CD40L interactions and IL-21 in sanroque mice
promote survival of autoreactive B cells and their development
into plasma cells.
In contrast to follicular B cells, B-1 and marginal zone B
cells preferentially generate short-lived (extrafollicular) plasma
cells. Although GC responses generally require CD40–CD40L
interactions to initiate plasma cell differentiation, differentia-
tion of human marginal zone-derived memory B cells is CD40-
independent, but IL-21 and BAFF-dependent (17).
Role of TLR in Plasma Cell Differentiation
In mice, endosomal TLRs are critical for the production of lupus
autoantibodies. In MRL/lpr mice, anti-Sm autoantibodies are
abolished in TLR7-deficient mice, whereas anti-dsDNA autoan-
tibodies are absent in TLR9-deficient mice (25). Nevertheless,
disease progression is ameliorated by TLR9 in MRL/lpr mice.
In contrast, both anti-Sm/RNP and anti-dsDNA autoantibodies
are TLR7-dependent in pristane-induced lupus (26). Production
of anti-Sm/RNP autoantibodies is driven by dual engagement of
the BCR (by the protein components of U1 snRNPs) and TLR7
(by U1 RNA) (27). TLR signaling in memory B cells may play a
role in maintaining serological memory by driving their terminal
differentiation (28), though the role of B-cell-intrinsic, polyclonal
TLR signaling in maintaining antigen-specific antibody levels
is controversial (29), possibly because the requirement for TLR
signaling may differ depending on the nature of the antigen.
This is illustrated by antibody responses to virus-like particles
(VLPs). Using a soluble TLR9 ligand as adjuvant, dendritic cell
but not B-cell MyD88 expression is needed to enhance antibody
production. In contrast, when the TLR9 ligand is incorporated
into aVLP, B-cell-intrinsic expression of TLR9/MyD88 is required
(30, 31). This may reflect enhanced delivery of nucleic acid to
endosomes containing TLR9. Since their nucleic acid constituents
are less susceptible to endosomal degradation when associated
with proteins, DNA-protein (e.g., chromatin) and RNA-protein
(e.g., Sm/RNP, U1 snRNPs) autoantigens may resemble VLPs.
Ligands for the endosomal TLRs (TLR3, TLR7, TLR8, TLR9)
are potent adjuvants (32). The pro-inflammatory effects of TLR
signaling play a role in their “adjuvanticity.” TLR7 is encoded on
the X-chromosome, one copy of which is inactivated in female
cells. Male BXSB (Yaa) mice, which have a second active copy
of the Tlr7 gene on the Y chromosome, develop a spontaneous
lupus syndrome with increased IL-21 and anti-dsDNA autoanti-
body production, and glomerulonephritis (33). In B6 mice, levels
of anti-RNA autoantibodies are correlated with the Tlr7 copy
number (34).
In addition to the level of TLR expression, subcellular distribu-
tion is critical for promoting inflammatory responses to foreign
nucleic acids and preventing inappropriate responses to autolo-
gous nucleic acids. TLR7 and TLR9 remain inactive until they are
proteolytically cleaved inside acidic endosomes. The endoplasmic
reticulum-resident protein UNC93B1 controls intracellular traf-
ficking of endosomal TLRs, regulating their activity and helping
to prevent recognition of endogenous nucleic acids. By compet-
ing with TLR7 for UNC93B1, TLR9 plays an anti-inflammatory
role, as illustrated by mutations that abolish the preference of
UNC93B1 for TLR9, resulting in lethal TLR7-mediated inflam-
matory disease (35, 36).
Levels of Autoantibodies Against Diverse
Self-Antigens in SLE Patients
Titers of IgG autoantibodies against RNA-protein autoantigens,
such as U1 snRNPs can be as high as 1:106 and these lev-
els typically are maintained for many years (37). This is much
higher than reported in other autoimmune diseases or following
immunization with exogenous foreign antigens. An important
difference between autoantibody responses in SLE vs. those in
other disorders, such as T1D or autoimmune thyroid disease, is
the physical nature of the autoantigens. Autoantibodies in T1D
recognize pancreatic antigens, such as insulin, glutamic acid dehy-
drogenase, and Pdx-1, which are not associated with nucleic acids.
These autoantibodies are specific for T1D, just as anti-Sm and
anti-dsDNA autoantibodies are specific for lupus. But diabetes-
specific autoantibodies typically are reported at much lower levels
than anti-Sm/RNP (38). We hypothesize that the explanation
for extremely high titers of “classic” lupus autoantibodies such
as anti-Sm, RNP, Ro (SS-A), and La (SS-B) is their association
with endogenous adjuvant, in the form of nucleic acid. Other
autoantibodies reported in SLE (1) do not recognize nucleic acid-
protein antigens.We hypothesized that the lattermay be produced
at lower levels because they are not associated with endogenous
adjuvant.
To test this hypothesis, we examined autoantibody levels in
sera from 23 consecutive SLE patients seen in our Autoimmune
Disease Clinic and 13 healthy controls (Figure 1). ELISA wells
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FIGURE 1 | Serum autoantibodies in SLE.
(Continued)
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FIGURE 1 | Continued
Levels of serum IgG anti-U1A, dsDNA, insulin, and thyroglobulin
autoantibodies were tested by ELISA in 23 consecutive SLE patients and
13 controls. SLE was classified using the ACR criteria. Healthy controls age
and gender-matched had no history of systemic autoimmune disease.
These studies were reviewed and approved by the University of Florida
Institutional Review Board. (A) Antigens were coated on plastic wells at
0.8µg/ml and sera were diluted 1:500 for screening. (B) ELISA titration
curves (serial twofold dilutions) for the four sera most strongly reactive with
each antigen. Patient ID number is shown in the key. (C) Frequencies of
anti-dsDNA, anti-RNA-protein (rNP, anti-Sm, RNP, Ro/SS-A, and La/SS-B)
autoantibodies detected by commercial ELISAs in a cohort of 106 SLE
patients. Only 6% of the sera were unreactive with both dsDNA and the
ribonucleoprotein autoantigens.
were coated with four test antigens at 0.8µg/ml: recombinant
human U1A (a component of U1 snRNPs), double-stranded (ds)
DNA, human insulin, and human thyroglobulin. A positive reac-
tion was defined as 2 standard deviations above the mean of
controls. In this cohort, 18/23 SLE patients had anti-U1A autoan-
tibodies vs. 1/13 controls (at a low level) (P= 0.01) (Figure 1A).
For anti-dsDNA antibodies, 7/23 SLE patients vs. 0/13 controls
were positive (P= 0.03). In the case of anti-insulin autoantibod-
ies, 1/23 SLE patients and 0/13 controls were positive (P= 0.36,
NS), and the levels of autoantibodies were considerably lower
than anti-U1A or anti-dsDNA. Similarly, 2/23 SLE patients vs.
0/13 controls were positive for anti-thyroglobulin autoantibodies
(P= 0.35, NS). Consistent with the wide diversity of autoanti-
bodies in SLE (1), we identified patients whose sera were pos-
itive for anti-insulin autoantibodies (associated with T1D) and
anti-thyroglobulin autoantibodies (associated with autoimmune
“Hashimoto” thyroiditis). However, these patients did not have
either T1D or hypothyroidism. Serum from one patient (#2898)
gave a positive reaction with all four self-antigens, suggesting that
it may contain “polyreactive” IgG autoantibodies.
We next examined the titers of autoantibodies against each test
antigen in the four most strongly positive SLE sera. As shown
in Figure 1B, titers of autoantibodies against the RNA-protein
autoantigenU1Aweremarkedly higher than those against dsDNA
and the non-nucleic acid associated autoantigens insulin and
thyroglobulin. Additionally, anti-dsDNA titers were higher than
anti-insulin and anti-thyroglobulin.
Finally, we examined the frequency of anti-dsDNA and anti-
ribonucleoprotein (Sm, RNP, Ro/SS-A, or La/SS-B) autoanti-
bodies by commercial ELISA in a cohort of 106 SLE patients
meeting the Revised ACR Criteria for Classification of Lupus.
In these patients, 68% were positive for anti-dsDNA at some
time during their course, 76% for anti-ribonucleoprotein, and
50% for both anti-dsDNA and anti-ribonucleoprotein autoan-
tibodies (Figure 1C). Only 6% of the patients did not have
anti-DNA-protein or RNA-protein autoantibodies, a figure that
may over-estimate the true number, as we did not include
autoantibodies against RNA-protein autoantigens other than anti-
Sm/RNP/Ro/La.
Taken together, these data suggest that (1) SLE is charac-
terized by a high frequency of autoantibodies against nucleic
acid-protein autoantigens, whereas frequencies of autoantibodies
against the non-nucleic acid-associated autoantigens are consid-
erably lower and (2) in SLE patients, the levels of autoantibodies
against nucleic acid autoantigens (particularly RNA-proteins) is
markedly higher than autoantibodies against non-nucleic acid
associated autoantigens. Finally, although more speculative, the
subset of non-nucleic acid associated autoantibodies (e.g., anti-
insulin, anti-thyroglobulin)may be of limited clinical significance,
FIGURE 2 | Proposed model of autoantibody generation in SLE. SLE is
associated with genetic abnormalities that impair central or peripheral B-cell
tolerance. In the presence of T-cell help, autoreactive B cells that escape
censoring may develop into IgG-producing memory B cells. However, these
cells can circulate without producing autoantibodies. Following subsequent
antigen exposure, the memory cells enhance their expression of BLIMP-1 and
develop into autoantibody-secreting plasma cells. In the case standard
autoantigens, such as insulin, which engage only the B-cell receptor, the
stimulus to undergo terminal (plasma cell) differentiation is weaker than in the
case of RNA-associated autoantigens, such as U1A, which can activate
terminal B-cell differentiation via both the B-cell receptor and TLR7. This may
explain why levels of anti-U1A (RNP) autoantibodies are markedly higher than
anti-insulin autoantibody levels.
as none of the patients had either T1D or autoimmune thyroidi-
tis. However, we cannot exclude the possibility that they will
develop T1D or thyroid disease in the future. In contrast, anti-
RNP/Sm autoantibodies (such as anti-U1A) are implicated in
the production of pro-inflammatory cytokines, such as IFNα, by
plasmacytoid dendritic cells (39) and anti-dsDNA autoantibodies
can cause lupus nephritis (40).
Conclusion
Although 180 or more self-antigens have been reported as targets
in SLE (1), only a few are common. This subset, which includes
anti-Sm/RNP, anti-Ro/SS-A, anti-La/SS-B, anti-dsDNA, and sev-
eral others, consists primarily of nucleic acid (DNA or RNA) asso-
ciated proteins. Although lupus-like phenomena are associated
with genetic abnormalities that impair central or peripheral B-
cell tolerance (e.g., PTPN22, Btk, Lyn, Tnfsf13b), large numbers
of autoreactive B cells can circulate without producing autoanti-
bodies (5). Thus, regulation of the balance between BCL-6 and
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PRDM1 (BLIMP-1) expression may play a role in determining
whether or not clinically significant levels of autoantibodies are
produced. T-cell-derived signals (CD40L, SAP), cytokines (BAFF,
IL-21), and TLRs (especially TLR7), all promote terminal B-cell
differentiation by up-regulating the expression of PRDM1. We
hypothesize that the enhanced survival of autoreactive B cells in
SLE in the setting of BCR engagement and sub-optimal levels of T-
cell-derived maturation signals or cytokines may explain the wide
diversity of autoantibodies detected in SLE (Figure 2). The pro-
duction of relatively low levels of anti-insulin, anti-thyroglobulin,
and anti-dsDNA autoantibodies (Figure 1B) is consistent with
that possibility. The repetitive nature of DNA antigen may further
drive plasma cell differentiation by enhancing the strength of
BCR signaling. In contrast, dual engagement of the BCR and
TLR7 by ribonucleoprotein autoantigens may deliver a more
potent terminal differentiation signal, explaining the high levels
of autoantibodies against ribonucleoprotein antigens (Figure 2).
TLR7 engagement also may play a key role in the inflamma-
tory manifestations of SLE by driving the production of IFNα,
TNFα, IL-12 (IFNγ), and other pro-inflammatory cytokines.
Thus, while SLE is characterized by a panoply of autoantibod-
ies, the clinically significant autoantibodies are probably more
restricted.
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